Back to Search Start Over

Apoptosis induction in acute promyelocytic leukemia cells through upregulation of CEBPα by miR-182 blockage.

Authors :
Sharifi M
Fasihi-Ramandi M
Sheikhi A
Moridnia A
Saneipour M
Source :
Molecular biology research communications [Mol Biol Res Commun] 2018 Mar; Vol. 7 (1), pp. 25-33.
Publication Year :
2018

Abstract

MicroRNAs (miRNAs) involved in regulation of the genes. The CCAAT/enhancer-binding protein-α ( CEBPα ) is a crucial transcription factor for normal hematopoiesis and cell cycle that frequently disrupted in human acute myeloid leukemia (AML). The miR-182 up-regulation in several malignant diseases such as AML was reported, in the other hand bioinformatics analysis revealed CEBPα targeted by miR-182.miR-182-5p inhibition in human acute promyelocytic leukemia (APL) cell line was performed by using locked nucleic acid (LNA) and subsequently miR-182-5p and CEBPα expression, apoptosis, necrosis and cell proliferation were measured. After LNA-anti-miR-182-5p transfection to cells at different time points, miR-182-5p down regulation and CEBPα overexpression was revealed in the LNA-anti-miR group compared to the control groups. The cell viability was meaningfully varied between LNA-anti-miR and control groups. Increasing of the apoptotic ratio was linked to miR-182-5p inhibition in the LNA-anti-miR group rather than other groups. Similarly, the necrotic ratio in the LNA-anti-miR group was higher.Our results supported the hypothesis that miR-182-5p inhibition can reduce the cell viability predominantly due to induces apoptosis and necrosis. The present results can apply in translational medicine for investigation of antisense therapy and drug development in leukemia.<br />Competing Interests: The authors declare that they have no conflict of interest.

Details

Language :
English
ISSN :
2322-181X
Volume :
7
Issue :
1
Database :
MEDLINE
Journal :
Molecular biology research communications
Publication Type :
Academic Journal
Accession number :
29911120
Full Text :
https://doi.org/10.22099/mbrc.2018.27625.1297